Life Science Today

Life Science Today

By Noah Goodson, PhDBusinessScienceEducation
Download on the App Store

Life Science Today episodes

  • Life Science Today 024 – Vaccine EAU, 70+ IPOs, Gilead

    Originally Published as The Niche Podcast

    Vaccines are here, capitalizing on capital with IPOs, and Gilead targets Hepatitis D.



    Sponsors
    https://www.thescopemethod.com


    Story References
    https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19
    https://www.abcellera.com/news/2020-12-10-abcellera-announces-pricing-of-ipo
    https://www.certara.com/pressrelease/certara-announces-pricing-of-its-upsized-initial-public-offering/
    https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4d-molecular-therapeutics-announces-upsized-pricing-initial
    https://www.nanobiotix.com/wp-content/uploads/2020/12/PR-Pricing.pdf
    https://www.gilead.com/news-and-press/press-room/press-releases/2020/12/gilead-sciences-to-acquire-myr-gmbh


    Music by Luke Goodson
    https://www.soundcloud.com/lukegoodson

     
    Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

    7 min
  • Life Science Today 023 – Everlywell, Bayer + Atara, and Moderna

    Originally Published as The Niche Podcast

    Everlywell expands at-home testing, Bayer and Atara strike deal, and Moderna heads to the FDA.


    Sponsors

    https://www.thescopemethod.com


    Story References

    https://www.prnewswire.com/news-releases/everlywell-announces-175-million-financing-to-expand-consumer-lab-testing-and-digital-health-offerings-301185355.html

    https://media.bayer.com/baynews/baynews.nsf/id/Bayer-Atara-Biotherapeutics-enter-strategic-collaboration-generation-mesothelin-targeted-CAR-T?Open&parent=news-overview-category-search-en&ccm=020

    https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study


    Music by Luke Goodson

    https://www.soundcloud.com/lukegoodson

    Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

    6 min
  • Life Science Today 022 – Interview with COVID19 Survivor

    Originally Published as The Niche Podcast

    This week, we take a thanksgiving break from the news cycle to bring you a special interview with a COVID survivor and healthcare worker, Trenton Barrick. He shares an inside perspective on the healthcare industry as well as his personal experience being hospitalized with COVID19.

    Sponsors
    https://www.thescopemethod.com

    Trenton's Website
    https://www.nmtworks.com/

    Aphasia Choir
    https://singaphasia.com/

    Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.



    44 min
  • Life Science Today 021 – Pfizer, mRNA Vaccine Function, and Novartis + Mesoblast

    Originally Published as The Niche Podcast

    Pfizer submits to the FDA, how mRNA vaccines work, and Novartis drops a billion, but really only $50 million



    Story References
    https://www.biospace.com/article/pfizer-and-biontech-to-submit-covid-19-vaccine-to-fda-for-emergency-use-today/
    https://www.biospace.com/article/releases/stoke-therapeutics-announces-pricing-of-97-5-million-public-offering/
    https://www.novartis.com/news/media-releases/novartis-secures-exclusive-rights-potential-acute-respiratory-distress-syndrome-cell-therapy

     
    Sponsors
    https://www.thescopemethod.com

    Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

     

    9 min
  • Life Science Today 020 – Vaccines, NightWare, Agios, Silverback

    Originally Published as The Niche Podcast

    COVID19 vaccine news, an app to stop nightmares, Agios targets Sickle Cell disease, and Silverback files to go public.



    Sponsors
    https://www.thescopemethod.com


    Story References
    https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against
    https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy
    https://night-ware.com/news
    https://investor.agios.com/news-releases/news-release-details/agios-announces-fda-orphan-drug-designation-granted-mitapivat-0
    https://sec.report/Document/0001193125-20-290236/


    Music by Luke Goodson
    https://www.soundcloud.com/lukegoodson

    Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

    8 min
  • Life Science Today 019 – Biogen, Novo Nordisk, and Merck

    Originally Published as The Niche Podcast

    Aducanumab skeptics, Novo Nordisk and Merck make acquisitions, but first a market update.


    Sponsors
    https://www.thescopemethod.com

     

    Story References
    https://www.sciencemag.org/news/2020/11/biogen-s-alzheimer-s-drug-candidate-takes-beating-fda-advisers
    https://www.merck.com/news/merck-announces-third-quarter-2020-financial-results/
    https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=33374


    Music by Luke Goodson
    https://www.soundcloud.com/lukegoodson

    Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

     

    8 min
  • Life Science Today 018 – Syneos Health, Apellis, and Patient Enrollment

    Originally Published as The Niche Podcast

    Syneos Health acquires Synteract, Apellis strikes a billion-dollar deal, and clinical trial patient enrollment, but first a market update.



    Sponsors
    https://www.thescopemethod.com


    Story References
    https://www.investor.syneoshealth.com/news-releases/news-release-details/syneos-health-acquire-synteract-top-cro-provider-emerging
    https://www.prnewswire.com/news-releases/new-greenphire-data-indicates-clinical-trial-industrys-swift-rebound-patient-enrollment-reaches-pre-pandemic-levels-301159557.html?tc=eml_cleartime
    https://investors.apellis.com/news-releases/news-release-details/apellis-and-sobi-enter-collaboration-global-co-development-and
     

    Music by Luke Goodson
    https://www.soundcloud.com/lukegoodson

    Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

     

    8 min
  • Life Science Today 017 – Covance, IQVIA, ThermoFisher, Convalescent Plasma, Remdesivir

    Originally Published as The Niche Podcast

    This week, siteless with vision, IQVIA back on track, 36%, convalescent plasma, and Remdesivir approved.




    Sponsors

    https://www.thescopemethod.com

     

    Story References

    https://www.businesswire.com/news/home/20201020005645/en/LabCorp-Transforms-the-Clinical-Trial-Experience-And-Streamlines-the-Drug-Development-Process

    https://www.businesswire.com/news/home/20201020005345/en/IQVIA-Reports-Third-Quarter-2020-Results-Raises-Full-Year-2020-Guidance-and-Provides-2021-Outlook

    https://www.prnewswire.com/news-releases/thermo-fisher-scientific-reports-third-quarter-2020-results-301156312.html

    https://www.bmj.com/content/371/bmj.m3939

    https://www.nejm.org/doi/full/10.1056/NEJMoa2007764
     

    Music by Luke Goodson

    https://www.soundcloud.com/lukegoodson

    Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

     

    8 min
  • Life Science Today 016 – Slow, Sickle-Cell, CRO Mergers, Praxis IPO, Wasp Venom

    Originally Published as The Niche Podcast

    Failures in sickle-cell therapy, CRO mergers in Asia, Praxis IPO, and wasp venom.



    Sponsors

    https://www.thescopemethod.com

    Story References

    https://ir.cyclerion.com/news-releases/news-release-details/cyclerion-announces-phase-2-strong-scd-study-results-patients

    https://ir.cyclerion.com/news-releases/news-release-details/cyclerion-announces-positive-data-iw-6463-cns-translational

    https://novotech-cro.com/news/asia-pacific-has-record-year-clinical-trials-according-novotech 

    https://investors.praxismedicines.com/press-releases

    https://www.pnas.org/content/early/2020/10/07/2012379117


    Music by Luke Goodson

    https://www.soundcloud.com/lukegoodson

    Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

     

    8 min
  • Life Science Today 015 – CRISPR, Tinnitus, Takeda, and Political-Science

    Originally Published as The Niche Podcast

    Nobel prizes, clinical trials for tinnitus, Takeda’s billion-dollar deal, and the White House keeps science political



    Sponsors
    https://www.thescopemethod.com


    Story References
    https://www.nobelprize.org/prizes/chemistry/2020/summary/
    https://stm.sciencemag.org/content/12/564/eabb2830
    https://www.nytimes.com/2020/10/05/us/politics/coronavirus-vaccine-guidelines.html
    https://www.businesswire.com/news/home/20201008005340/en/


    Music by Luke Goodson
    https://www.soundcloud.com/lukegoodson

    Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

     

    7 min

About Life Science Today

From the publisher's feed

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news…